Skip to Main Content

Dozens of advocacy groups are urging one of the largest American universities not to pursue a patent for a pricey cancer drug in India, opening another front in an ongoing battle over access to the medicine.

At issue is the Xtandi prostate cancer treatment, which was originally invented at the University of California, Los Angeles, and has become a flashpoint in a wider debate in the United States over the extent to which Americans should pay high prices for medicines that were developed, at least in part, with taxpayer dollars.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Amazing what happens when you put a calculator to $44.77 per pill x 4/day … x 365. The cost ends up slightly north of $65,000/ year – what sounded possibly reasonable ends up at just over half of the US price of $129,000/ year. Another flash point where ‘things may get interesting.’

Comments are closed.